Tiotropium

also known as tiotropium bromide · Spiriva · Spiriva HandiHaler · Spiriva Respimat · TIO · Tiotropium Bromide Monohydrate · Ba679BR · Bromuro de Tiotropio · +11 more

Other / unclassified

Developed for: chronic obstructive pulmonary disease · asthma · cystic fibrosis · childhood onset asthma · chronic bronchitis · allergic asthma · bronchial disorder · bronchitis
+4 more
· obstructive lung disease · pulmonary emphysema · spinal cord injury · bronchiectasis
Investigated by: Boehringer Ingelheim · Pfizer · GlaxoSmithKline · Novartis Pharmaceuticals · 3M · Solventum US LLC
+64 more
· AstraZeneca · Novartis · University of Dundee · University of Saskatchewan · Baim Institute for Clinical Research · Brigham and Women's Hospital · Milton S. Hershey Medical Center · National Heart, Lung, and Blood Institute (NHLBI) · Orion Corporation, Orion Pharma · Quotient Clinical · Tenovus Scotland · Teva Branded Pharmaceutical Products R&D, Inc. · Theravance Biopharma · American Academy of Family Physicians National Research Network · Assiut University · Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS · Carelon Research · Centre Hospitalier Universitaire de Besancon · Children's Hospital Medical Center, Cincinnati · Erasme University Hospital · Federal State Budgetary Institution, Pulmonology Scientific Research Institute · Federal University of São Paulo · Fraunhofer-Institute of Toxicology and Experimental Medicine · General University Hospital, Prague · Guangzhou Institute of Respiratory Disease · Hamilton Health Sciences Corporation · Helsinki University Central Hospital · Henan University of Traditional Chinese Medicine · Huashan Hospital · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · IRCCS Azienda Ospedaliero-Universitaria di Bologna · Imperial College London · Irmandade Santa Casa de Misericórdia de Porto Alegre · James J. Peters Veterans Affairs Medical Center · Kindeva Drug Delivery · Laval University · Massachusetts General Hospital · Mayo Clinic · Medical University of Bialystok · Moscow State University of Medicine and Dentistry · Mylan Inc. · NHS Greater Glasgow and Clyde · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Nemours Children's Clinic · Nephron Pharmaceuticals Corporation · Neutec Ar-Ge San ve Tic A.Ş · Olmsted Medical Center · Parexel · Pearl Therapeutics, Inc. · Queen's University · RWTH Aachen University · Rho, Inc. · Royal Free and University College Medical School · Seoul National University Hospital · Shanghai Zhongshan Hospital · Simbec Research · Taipei Veterans General Hospital, Taiwan · Tanta University · ThomasTruncale · University Hospital, Bordeaux · University Hospital, Ghent · Università degli Studi di Ferrara · Viatris Inc. · Yonsei University

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed asthma 1 milestone
Filed	US (FDA)	Spiriva Respimat	asthma	2014-11-03	“accepted for review the New Drug Application (NDA) for Spiriva ® Respimat ® (tiotropium bromide) Inhalation Spray” prnewswire.com ↗
Filed chronic obstructive pulmonary disease 1 milestone
Filed	US (FDA)	—	chronic obstructive pulmonary disease	2014-08-19	“the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol” prnewswire.com ↗
Approved Indication not stated 3 milestones
Label expansion	US (FDA)	SPIRIVA RESPIMAT	—	2017-02-15	fda.gov ↗
Label expansion	US (FDA)	SPIRIVA	—	2009-12-17	fda.gov ↗
Approved	US (FDA)	SPIRIVA	—	2004-01-30	fda.gov ↗

Trials 192 · started per year

today

US approved 2004

1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT05748977	Feb 2023 → Feb 2024	chronic obstructive pulmonary disease	Assiut University	Unknown	No outcome recorded
Phase 0	NCT03155204	Apr 2017 → Jan 2018	—	Solventum US LLC	Completed	No outcome recorded
Phase 0	NCT00870896	Feb 2008 → Feb 2009	chronic bronchitis	ThomasTruncale	Completed	No outcome recorded
Phase 123 trials · 1 met primary
Phase 1	NCT05246046	Feb → Aug 2022	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03945344	May → Jun 2019	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03246581	Jul 2017 → Jan 2018	—	Kindeva Drug Delivery	Completed	No outcome recorded
Phase 1	NCT02969317	Feb → Jun 2017	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03302065	May → Sep 2016	—	Solventum US LLC	Completed	No outcome recorded
Phase 1	NCT02676297	Jan → May 2016	—	Solventum US LLC	Completed	No outcome recorded
Phase 1	NCT02627625	Nov 2015 → Mar 2016	—	Solventum US LLC	Completed	No outcome recorded
Phase 1	NCT02573155	Oct 2015 → Aug 2016	asthma, chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 1	NCT02441114	Jul → Oct 2015	chronic obstructive pulmonary disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT01703845	Oct 2012 → Mar 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT01309139	Mar → Jun 2011	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00555022	Dec 2007 → Apr 2008	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02259959	Apr → Sep 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172534	Sep 2006 → Sep 2008	cystic fibrosis	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02259946	Apr → Jul 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02254174	Mar → Jul 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00279019	Dec 2005 → Jun 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00257452	Oct 2004 → Jul 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02263976	Aug 2003 → Jun 2004	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172781	Jan → Apr 2001	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172417	Jul → Nov 2000	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02177305	Oct → Dec 1998	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172339	Apr → Dec 1998	impaired renal function disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT01785433	Jan → Jul 2013	chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 231 trials · 12 met primary · 1 missed
Phase 2	NCT04990167	Jan 2022 → Oct 2025	childhood onset asthma	Nemours Children's Clinic	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT04780984	Nov 2020 → Apr 2021	chronic obstructive pulmonary disease	Nephron Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 2	NCT04179461	Mar 2018 → Oct 2019	childhood onset asthma	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2	NCT02203474	Aug 2014	chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT02586649	Jul 2014 → Dec 2019	spinal cord injury	James J. Peters Veterans Affairs Medical Center	Completed	No outcome recorded
Phase 2	NCT02030535	Jan → Jun 2014	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT01696071	Sep 2012 → Jun 2013	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01634113	Jul 2012 → Dec 2014	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01383499	Aug 2011 → Sep 2012	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT01172925	Nov 2010 → Jun 2016	non-small cell lung carcinoma	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 2	NCT01233284	Nov 2010 → Jan 2012	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT01222533	Oct 2010 → Nov 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Missed primary
Phase 2	NCT01152450	Jul 2010 → Aug 2011	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT01122680	May 2010 → Apr 2011	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT01040403	Jan 2010 → Feb 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00737100	Sep 2008 → Apr 2010	cystic fibrosis	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00696020	Jun 2008 → Feb 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00557700	Jan 2008 → May 2010	asthma	University Hospital, Ghent	Completed	No outcome recorded
Phase 2	NCT00528996	Sep 2007 → May 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00422604	Oct 2006 → May 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00365560	Aug 2006 → Nov 2007	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00350207	Jul 2006 → Sep 2008	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 2	NCT00292448	Feb 2006 → Mar 2007	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00325169	Dec 2005 → Aug 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT00128440	Aug 2005 → Sep 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242266	Jul 2005 → Jun 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00122434	Jul 2005 → May 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242253	Sep 2003 → Jul 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02238119	Feb → Aug 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02172352	Jul 1998 → May 1999	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02175342	Mar 1998 → Apr 1999	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT03358147	Dec 2017 → Sep 2019	asthma	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 369 trials · 21 met primary · 7 missed
Phase 3	NCT05927155	Jun 2021 → Mar 2022	chronic obstructive pulmonary disease	Erasme University Hospital	Completed	No outcome recorded
Phase 3	NCT03169504	May 2017 → May 2018	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	Mixed
Phase 3	NCT03095456	Mar → Nov 2017	chronic obstructive pulmonary disease	Mylan Inc.	Completed	Missed primary
Phase 3	NCT02796677	Jul 2016 → Jun 2017	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 3	NCT02683668	Feb 2016 → Jan 2018	chronic obstructive pulmonary disease	Imperial College London	Completed	No outcome recorded
Phase 3	NCT02066298	Jul 2014 → May 2018	asthma	Milton S. Hershey Medical Center	Completed	Missed primary
Phase 3	NCT02085161	Mar 2014 → Aug 2015	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT02006732	Nov 2013 → Oct 2014	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01969721	Oct 2013 → Jan 2015	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01634139	Jul 2012 → Jun 2015	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01634152	Jul 2012 → May 2015	asthma	Boehringer Ingelheim	Completed	Mixed
Phase 3	NCT01559116	Mar 2012 → Aug 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01536262	Feb 2012 → Sep 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01525615	Feb 2012 → Sep 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01533935	Feb 2012 → Nov 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Mixed
Phase 3	NCT01431287	Sep 2011 → Nov 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01431274	Sep 2011 → Sep 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01340209	Apr 2011 → Apr 2013	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01290874	Mar 2011 → Jul 2013	asthma	Brigham and Women's Hospital	Completed	Missed primary
Phase 3	NCT01316380	Mar 2011 → Apr 2012	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01277523	Jan 2011 → Oct 2013	asthma	Boehringer Ingelheim	Completed	Missed primary
Phase 3	NCT01257230	Dec 2010 → Dec 2013	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01179347	Sep 2010 → Mar 2012	cystic fibrosis	Boehringer Ingelheim	Completed	Missed primary
Phase 3	NCT01172808	Aug 2010 → Nov 2012	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01172821	Aug 2010 → Nov 2012	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01119937	May 2010 → Nov 2011	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01012765	Nov 2009 → Jan 2011	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00999908	Oct 2009 → Mar 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00772538	Oct 2008 → Jul 2011	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00776984	Oct 2008 → Jul 2011	asthma	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00565266	May 2008 → May 2010	asthma	Milton S. Hershey Medical Center	Completed	Met primary
Phase 3	NCT00673478	May 2008 → Jun 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00662792	Apr 2008 → Jul 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Mixed
Phase 3	NCT00668772	Apr → Nov 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00615459	Feb → Dec 2008	chronic obstructive pulmonary disease	Novartis	Completed	Met primary
Phase 3	NCT00387088	Sep 2006 → Jan 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00239460	Jul 2003 → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00144326	Jul 2003 → Oct 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00239434	Jun 2003 → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00168831	Feb 2003 → Jun 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00168844	Jan 2003 → Jun 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT00144339	Dec 2002 → Feb 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Missed primary
Phase 3	NCT00239447	Nov 2002 → Apr 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274092	Sep 2002 → Oct 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00157235	Sep 2002 → Apr 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00281567	Aug 2002 → Jul 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274040	Jul 2002 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274560	May 2002 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172794	May 2002 → Oct 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172456	May → Oct 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274053	Apr 2002 → Apr 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274573	Mar → Oct 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00277264	Jan 2002 → May 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274547	Sep 2001 → Feb 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172443	Jun 2001 → May 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172469	May 2001 → Apr 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274521	May 2001 → Feb 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274027	Jan 2001 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274534	Dec 2000 → Jul 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172807	Dec 2000 → Sep 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172391	Nov 2000 → Aug 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274508	Oct 2000 → Jan 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274014	Oct 2000 → Oct 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172430	Sep 2000 → May 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172378	May 2000 → Jan 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172300	Jun 1999 → Nov 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02173691	Feb 1999 → May 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172287	Feb 1999 → May 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172326	Feb → Sep 1998	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 458 trials · 14 met primary · 8 missed
Phase 4	NCT07827859	Nov 2026 → May 2029 expected	bronchial disorder	General University Hospital, Prague	Not yet recruiting	No outcome recorded
Phase 4	NCT06679465	Jan 2025 → Jan 2027 expected	asthma	University of Saskatchewan	Not yet recruiting	No outcome recorded
Phase 4	NCT05165485	Jan 2022 → Nov 2023	chronic obstructive pulmonary disease	Theravance Biopharma	Completed	Missed primary
Phase 4	NCT04648813	Nov 2020 → Apr 2021	allergic asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT04231214	Jan 2020 → Apr 2023	chronic obstructive pulmonary disease	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
Phase 4	NCT04223843	Jan → Sep 2020	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT03964207	Nov 2019 → Oct 2021	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Missed primary
Phase 4	NCT03662711	Nov 2018 → Oct 2022	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Terminated	No outcome recorded
Phase 4	NCT03478683	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03478696	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03474081	Mar 2018 → Jul 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT03265145	Sep 2017 → Sep 2020	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03240575	Aug 2017 → Apr 2019	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Missed primary
Phase 4	NCT03055988	Mar 2017 → Mar 2018	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Missed primary
Phase 4	NCT02813200	Jan 2017 → Feb 2019	chronic obstructive pulmonary disease	University Hospital, Bordeaux	Completed	No outcome recorded
Phase 4	NCT03425617	Jan 2017 → Jun 2018	chronic obstructive pulmonary disease	Queen's University	Completed	No outcome recorded
Phase 4	NCT02812862	Aug 2016 → Aug 2017	chronic obstructive pulmonary disease	RWTH Aachen University	Withdrawn	No outcome recorded
Phase 4	NCT02799784	Jul 2016 → Apr 2017	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT02682862	Jul 2016 → May 2019	asthma	University of Dundee	Completed	Met primary
Phase 4	NCT02567214	Jun 2016 → Nov 2018	chronic obstructive pulmonary disease	Laval University	Completed	No outcome recorded
Phase 4	NCT03199976	Apr 2016 → Nov 2020	asthma, bronchitis, obstructive lung disease	Helsinki University Central Hospital	Terminated	Met primary
Phase 4	NCT02872090	Mar 2016 → Jun 2021	chronic obstructive pulmonary disease	Centre Hospitalier Universitaire de Besancon	Completed	No outcome recorded
Phase 4	NCT02622243	Nov 2015 → Mar 2016	asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT02541006	Nov 2014 → Apr 2015	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT04520230	Oct 2014 → Dec 2019	chronic obstructive pulmonary disease	Tanta University	Completed	No outcome recorded
Phase 4	NCT02546349	Jul 2014 → Dec 2015	chronic obstructive pulmonary disease	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT02125734	Apr 2014 → Jan 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Met primary
Phase 4	NCT01959516	Feb → Oct 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Met primary
Phase 4	NCT02039011	Feb 2014 → Jul 2016	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01922271	Aug 2013 → Jan 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Met primary
Phase 4	NCT01693003	Mar → Oct 2013	chronic obstructive pulmonary disease	Irmandade Santa Casa de Misericórdia de Porto Alegre	Completed	Missed primary
Phase 4	NCT01794780	Feb 2013 → May 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01762800	Feb 2013 → Sep 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01656005	Aug 2012 → Jul 2016	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01483625	Nov 2011 → Dec 2012	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Missed primary
Phase 4	NCT01644734	Nov 2011 → Mar 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01397890	Jul 2011 → Jun 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 4	NCT01465906	Nov 2010 → Nov 2011	chronic obstructive pulmonary disease	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
Phase 4	NCT01112241	Apr → May 2010	transplant-related bronchiolitis obliterans	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Completed	No outcome recorded
Phase 4	NCT00783250	Sep 2008 → Aug 2011	chronic obstructive pulmonary disease	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Terminated	No outcome recorded
Phase 4	NCT00680056	Nov 2007 → Dec 2008	chronic bronchitis, pulmonary emphysema	Federal University of São Paulo	Completed	Met primary
Phase 4	NCT00530842	Sep 2007 → Jan 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Mixed
Phase 4	NCT00525512	Aug 2007 → Jun 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Missed primary
Phase 4	NCT00523991	Apr 2007 → Jul 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00388882	Oct 2006 → Oct 2007	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00578968	Oct 2006 → Aug 2008	chronic obstructive pulmonary disease	Mayo Clinic	Completed	Missed primary
Phase 4	NCT00359788	Jul 2006 → Apr 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00335621	Jun 2006 → Dec 2007	chronic obstructive pulmonary disease	NHS Greater Glasgow and Clyde	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT00152984	Dec 2004 → Apr 2006	asthma, chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00106821	Jun 2004 → Aug 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00144196	Mar 2004 → Jul 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02172508	Jan → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 4	NCT00239421	Nov 2003 → Sep 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00239499	Sep 2003 → Aug 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00361959	Jun 2003 → Feb 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239408	Dec 2002 → Apr 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00405236	Oct 2002 → Jan 2005	chronic obstructive pulmonary disease	Royal Free and University College Medical School	Completed	No outcome recorded
Phase 4	NCT00274079	Oct 2002 → Oct 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary

Phase not applicable6 trials
—	NCT07541378	Mar 2024 → Feb 2025	chronic obstructive pulmonary disease	Medical University of Bialystok	Suspended	No outcome recorded Stop: Enrollment
—	NCT04994574	Aug 2021 → Jul 2024	chronic obstructive pulmonary disease	Yonsei University	Completed	No outcome recorded
—	NCT04137029	Apr 2019 → Jul 2020	reactive airway disease	Federal State Budgetary Institution, Pulmonology Scientific Research Institute	Unknown	No outcome recorded
—	NCT03842839	Oct 2018 → Dec 2022	—	Guangzhou Institute of Respiratory Disease	Unknown	No outcome recorded
—	NCT03258749	Nov 2017 → Aug 2018	chronic obstructive pulmonary disease	Huashan Hospital	Unknown	No outcome recorded
—	NCT00706446	Jun 2008 → Jun 2010	asthma	Brigham and Women's Hospital	Terminated	No outcome recorded Stop: Business
Comparator or background therapy134 trials
Phase 1	NCT06254664 Background	Oct 2022 → Jul 2023	chronic obstructive pulmonary disease	Xiromed LLC	Completed	No outcome recorded
Phase 1	NCT04850144 Comparator	Apr → Oct 2021	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03400241 Comparator	Feb → Apr 2018	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03097380 Comparator	Apr → Dec 2017	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02059434 Comparator	Sep 2013 → Oct 2014	asthma, chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Show all 134 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 57

Date	Issuer	Release
2024-01-05	Theravance Biopharma	Results Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) theravance.com ↗ The study did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, change from baseline in trough forced expiratory volume in one second (FEV 1 ) at Day 85.
2023-07-26	Lupin Limited	Regulatory Lupin Receives Approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD lupin.com ↗ We are pleased to have received the approval for bioequivalent Tiotropium Dry Powder for Inhalation from TGA for the treatment of COPD in Australia.
2023-06-21	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler lupin.com ↗
2023-05-26	Lupin Limited	Regulatory Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD lupin.com ↗
2022-08-26	Lupin Limited	Regulatory Lupin Announces UK MHRA Approval of Lutio® (Tiotropium bromide inhalation powder) for Treatment of COPD lupin.com ↗ We are pleased to have received the approval of Lutio® from the MHRA for the treatment of chronic obstructive pulmonary disease (COPD), providing an effective and high-quality treatment option to patients in UK,” said Thierry Volle, President, EMEA, Lupin.
2021-09-03	Novartis Pharmaceuticals	Results Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions novartis.com ↗
2020-06-05	Novartis Pharmaceuticals	Results Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma novartis.com ↗ Once-daily Enerzair ® Breezhaler ® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving quality of life in people with uncontrolled asthma 1 .
2020-02-03	Boehringer Ingelheim	Results New Study Further Supports the Benefits of SPIRIVA RESPIMAT in the Treatment of Asthma prnewswire.com ↗ The study found that when adding Spiriva Respimat to ICS+LABA treatment, patients had fewer exacerbations and hospitalizations compared to those receiving an increased dose of ICS+LABA or continuing on high-dose of ICS+LABA, ultimately meeting the study's primary endpoint.
2018-10-11	Boehringer Ingelheim	Regulatory FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction prnewswire.com ↗ The FDA also revised the indication for Stiolto Respimat, which is now approved for the treatment of patients with COPD, including chronic bronchitis and emphysema.
2018-10-11	Theravance Biopharma	Results Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting theravance.com ↗ In the intent-to-treat population, the YUPELRI group showed improvements in trough FEV 1 and trough FVC on day 29 compared with tiotropium group; however, these differences did not reach statistical significance.
2018-05-22	Niox	Results Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza® Phase IV and Duaklir® Phase III Studies niox.com ↗ Sub-study : Duaklir® significantly improved night-time and 24-hour bronchodilation (area under the curve FEV1) compared with Spiriva® (150 mL vs 60 mL, p<0.001 and 167 mL vs 109 mL, p<0.05 respectively
2018-03-29	Boehringer Ingelheim	Results New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva® Respimat® prnewswire.com ↗ The DYNAGITO study results show that treatment with Stiolto Respimat resulted in a 7 percent lower rate of moderate-to-severe COPD exacerbations compared with Spiriva Respimat alone (p=0.0498), not reaching the targeted significance level (p=0.01) as pre-defined in the study.
2017-11-01	GlaxoSmithKline	Results GSK study demonstrates superiority of Anoro Ellipta to Stiolto Respimat in improving lung function in chronic obstructive pulmonary disease gsk.com ↗ This endpoint was met and, furthermore, UMEC/VI demonstrated superiority to TIO/OLO, with a difference in treatment effect of 52mL on trough FEV1 at week eight (UMEC/VI 180mL vs. TIO/OLO 128mL; 95% CI: 28, 77; p<0.001).
2017-09-07	AstraZeneca	Results Duaklir significantly improves lung function in COPD patients astrazeneca.com ↗ In addition, aclidinium bromide achieved its primary bronchodilation endpoint of demonstrating non-inferiority to tiotropium bromide 18µg once-daily.
2017-09-07	Niox	Results Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease niox.com ↗
2017-05-23	Boehringer Ingelheim	Results New Analyses Show SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Improves Breathing for People with Asthma Regardless of BMI or Allergic Status prnewswire.com ↗ Boehringer Ingelheim today announced new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.
2017-02-16	Boehringer Ingelheim	Regulatory FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children prnewswire.com ↗ Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, once-daily maintenance treatment of asthma in people age 6 and older.
2016-10-17	Boehringer Ingelheim	Results New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk prnewswire.com ↗ Boehringer Ingelheim today announced new data analyses from the Phase III TONADO® 1&2 trials that build upon existing evidence about the factors that increase the risk of a COPD exacerbation.
2016-09-06	Boehringer Ingelheim	Results Tiotropium RESPIMAT® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma prnewswire.com ↗ These new results showed significant lung function improvements for children with asthma and importantly confirm that the safety profile of tiotropium RESPIMAT in children aged one year and above is comparable to placebo.
2016-09-05	Boehringer Ingelheim	Results Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment prnewswire.com ↗ It suggests that only 4 in 100 people of the study population – with a history of frequent exacerbations and raised eosinophil levels (≥400 cells/µL) – may benefit by adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) and a long-acting beta 2 -agonist (salmeterol) to further reduce the risk of exacerbations.
2016-09-05	Boehringer Ingelheim	Results New Data: STIOLTO® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD prnewswire.com ↗ Boehringer Ingelheim today announced the first results from the Phase IIIb/IV PHYSACTO trial that showed STIOLTO RESPIMAT, combined with exercise training, helps people with COPD walk for longer periods of time compared to those receiving placebo.
2016-08-30	AstraZeneca	Results AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016 astrazeneca.com ↗ The benefit of Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) over a 24-hour period versus tiotropium bromide inhalation spray and placebo (abstract #PA994)
2016-05-18	GlaxoSmithKline	Results GSK presents efficacy data for Anoro® Ellipta® in COPD patients who remained symptomatic on tiotropium gsk.com ↗ These efficacy data demonstrate the improvement in lung function that can be achieved in patients with moderate COPD when changing treatment from monotherapy with tiotropium 18mcg to dual bronchodilation with Anoro Ellipta.
2016-04-08	Boehringer Ingelheim	Results Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy prnewswire.com ↗ For 80 percent of patients in the WISDOM study, the use of ICS on top of SPIRIVA® HANDIHALER® ‡ and a LABA** had no additional benefit in reducing the risk of exacerbations or 'flare-ups,' compared to SPIRIVA® HANDIHALER® ‡ and a LABA without ICS.
2016-03-07	Boehringer Ingelheim	Results New Analyses: Adding SPIRIVA® RESPIMAT® Effective for Uncontrolled Asthma - Regardless of Allergy Subtype prnewswire.com ↗ The addition of SPIRIVA® RESPIMAT® significantly improved lung function*.
2016-02-09	Boehringer Ingelheim	Results Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures prnewswire.com ↗ These newly published data show a lung function improvement among COPD patients with STIOLTO RESPIMAT across a range of commonly used measures of lung function.
2016-02-03	Boehringer Ingelheim	Regulatory SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents prnewswire.com ↗ The U.S. Food and Drug Administration (FDA) approved a once-daily dose of SPIRIVA RESPIMAT 2.5 µg (delivered in 2 puffs of 1.25 µg each) for the long-term maintenance treatment of asthma in people ages 12 and older.
2015-10-27	Boehringer Ingelheim	Results New Sub-Analyses Presented for STIOLTO RESPIMAT Across a Range of COPD Patient-Reported Outcomes Measures prnewswire.com ↗ One analysis showed significant lung function improvement, as measured by FEV 1 AUC 0–3 , with once daily STIOLTO RESPIMAT across a range of age groups of COPD patients
2015-10-20	GlaxoSmithKline	Results GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD gsk.com ↗ Results from the randomised, blinded* study 201316 showed that umeclidinium 62.5mcg once daily achieved a statistically significant improvement in lung function measured by trough forced expiratory volume in one second (FEV1) at 12 weeks (P<0.001), compared to tiotropium 18mcg administered once daily.
2015-09-28	Boehringer Ingelheim	Results New Head-to-Head STIOLTO RESPIMAT Data Presented at ERS Annual Congress prnewswire.com ↗ The results from the head-to-head ENERGITO® study build on the growing body of evidence supporting the ability of STIOLTO RESPIMAT to improve lung function in COPD patients.
2015-09-27	GlaxoSmithKline	Results GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint gsk.com ↗ The results of the analysis showed that the risk of experiencing a clinically important deterioration was significantly lower for patients on UMEC/VI 62.5/25mcg once daily compared to tiotropium 18mcg once daily (hazard ratio: 0.62; 95% confidence interval [CI]: 0.54, 0.71; p<0.001) or placebo (hazard ratio: 0.37; 95% CI: 0.30, 0.45; p<0.001) in an intention to treat population, based on analysis of time to first deterioration.
2015-08-17	Boehringer Ingelheim	Results New Published Data Show STIOLTO™ RESPIMAT® Provides Clinically Meaningful Improvements in COPD Health-Related Quality of Life Measure prnewswire.com ↗ Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials, which show STIOLTO RESPIMAT provided clinically meaningful improvements in SGRQ total score, compared to placebo, in patients with chronic obstructive pulmonary disease (COPD).
2015-05-26	Boehringer Ingelheim	Regulatory FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD prnewswire.com ↗ Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO ™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray.
2015-05-20	Boehringer Ingelheim	Results New Data Analyses on Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared to Tiotropium and Olodaterol Alone prnewswire.com ↗ In these analyses, we saw that tiotropium/olodaterol RESPIMAT demonstrated a statistically significant improvement in lung function compared to tiotropium and olodaterol alone for COPD patients across all stages of the disease (A-D).
2015-02-21	Boehringer Ingelheim	Results New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status prnewswire.com ↗ These data showed that the addition of tiotropium delivered via Respimat inhaler improved lung function in adults with asthma across a range of severities independent of underlying allergic status.
2014-11-03	Boehringer Ingelheim	Regulatory Boehringer Ingelheim Announces U.S. Filing Acceptance of New Drug Application for Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Treatment of Asthma prnewswire.com ↗ Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for Spiriva ® Respimat ® (tiotropium bromide) Inhalation Spray
2014-10-27	Boehringer Ingelheim	Results Boehringer Ingelheim Presents Data for the Co-Administration of Two Approved Products for COPD Patients prnewswire.com ↗ At Week 12, patients receiving T+O showed significant improvements in lung function, as measured by trough forced expiratory volume in one second (FEV 1 ) and FEV 1 area under the curve from 0-3 hours (FEV 1 AUC 0-3h ), compared to patients receiving tiotropium + placebo (T+P).
2014-10-17	GlaxoSmithKline	Results Data published on Anoro® Ellipta® demonstrate improved lung function compared to tiotropium gsk.com ↗
2014-09-25	Boehringer Ingelheim	Regulatory Boehringer Ingelheim Announces FDA Approval of Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Maintenance Treatment of COPD prnewswire.com ↗ Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva® Respimat® (tiotropium bromide) inhalation spray for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD patients.
2014-09-08	Boehringer Ingelheim	Results New Phase III Study Shows Investigational Tiotropium Improves Lung Function in Adolescent Patients with Symptomatic Asthma prnewswire.com ↗ The data presented at ERS show tiotropium 5 mcg delivered via the Respimat ® inhaler statistically significantly improved lung function, as measured by forced expiratory volume in one second (FEV 1 ) response, in adolescent patients with asthma who remain symptomatic.
2014-09-08	Boehringer Ingelheim	Results Boehringer Ingelheim Presents Pivotal Phase III Data for the Investigational Fixed-Dose Combination of Tiotropium + Olodaterol in COPD prnewswire.com ↗ The results from the TONADO™ studies showed that the combination has the potential to improve lung function compared to the individual components alone in people with COPD,
2014-08-19	Boehringer Ingelheim	Regulatory Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD prnewswire.com ↗ Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat ® inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
2014-08-14	Boehringer Ingelheim	Regulatory FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD prnewswire.com ↗ Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted [10 yes, 3 no] that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD patients.
2014-05-21	Boehringer Ingelheim	Results Boehringer Ingelheim Presents First Phase 3 Data on Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD prnewswire.com ↗ These data were presented as a late-breaking poster at the American Thoracic Society (ATS) 2014 International Conference.
2014-03-01	Boehringer Ingelheim	Results Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma Severities prnewswire.com ↗ Trough FEV 1 also improved with both doses of tiotropium versus placebo, independently of IgE and eosinophil count:
2013-10-28	Boehringer Ingelheim	Results New Data Provides Further Evidence of Lung Function Improvements in Severe Asthma with Tiotropium Delivered via the Respimat® Inhaler prnewswire.com ↗ These results add to data from the ongoing Phase 3 trial program that has previously shown positive results for tiotropium in severe asthma patients who remained symptomatic despite treatment with at least ICS/LABA.
2013-09-10	Boehringer Ingelheim	Results Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity prnewswire.com ↗ These new data from the MezzoTinA-asthma ® Phase 3 studies also showed the addition of once-daily tiotropium delivered via the Respimat ® inhaler provided a statistically significant improvement in asthma control responder rate, as measured by the Asthma Control Questionnaire (ACQ).
2013-09-08	Boehringer Ingelheim	Results Landmark TIOSPIR™ trial demonstrates comparable long-term safety of tiotropium delivered via Respimat® and HandiHaler® in COPD patients prnewswire.com ↗
2013-05-21	Boehringer Ingelheim	Results Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a Range of Symptomatic Asthma Patients at ATS 2013 prnewswire.com ↗ These results suggest tiotropium's promise independent of patients' baseline characteristics, providing an important clinical insight into tiotropium's potential in asthma treatment.
2013-02-23	Boehringer Ingelheim	Results Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status prnewswire.com ↗ Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma ™ program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas .
2012-09-03	Boehringer Ingelheim	Results First Phase III Data for Tiotropium in Symptomatic Asthma Patients Treated with ICS/LABA Published in the New England Journal of Medicine prnewswire.com ↗ For the third co-primary endpoint, in the pre-specified combined analysis of the two trials, the addition of tiotropium was associated with a 21% risk reduction (HR 0.79, P =0.03) in time to first severe exacerbation at 48 weeks.
2012-09-03	Boehringer Ingelheim	Results Boehringer Ingelheim Presents First Results of Phase II Study of Investigational COPD Combination prnewswire.com ↗ Significant improvements were seen for all combinations of doses tested (tiotropium 1.25, 2.5 and 5 microgram / olodaterol 5 microgram, 10 microgram) compared with the respective olodaterol monotherapies.
2012-09-03	Almirall, S.A.	Results Eklira® Genuair® provides meaningful and sustained bronchodilation from the first dose. Patients prefer the Genuair® inhaler over HandiHaler® almirall.com ↗ The benefits of this 24-hour bronchodilation vs placebo were seen from the first day of treatment with aclidinium and tiotropium (p<0.0001).
2012-08-28	Nxera Pharma UK Limited	Results QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients and filings in EU and Japan by end of year nxera.life ↗ Study showed QVA149 statistically significantly reduced overall exacerbation rates compared to glycopyrronium 50 mcg and open-label tiotropium 18 mcg1
2012-05-22	Boehringer Ingelheim	Results Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma prnewswire.com ↗ Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat ® Inhaler in adolescents with symptomatic, moderate persistent asthma.
2012-05-17	Nxera Pharma UK Limited	Results NVA237 Phase III GLOW2 data at American Thoracic Society (ATS) International Conference and Phase II clinical trial update nxera.life ↗ At this same time point, trough FEV1 for open-label (OL) tiotropium was 83 mL versus placebo (p <0.001).
2011-06-30	Nxera Pharma UK Limited	Results Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD nxera.life ↗ GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p＜0.001) with comparable efficacy to open-label tiotropium at 12 weeks

All press releases naming this drug 63 releases

Date	Issuer	Release
2024-01-05	Theravance Biopharma	Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) theravance.com ↗
2023-08-16	Lupin Limited	Lupin Launches Tiotropium Dry Powder Inhaler for the Treatment of COPD in the United States lupin.com ↗
2023-07-26	Lupin Limited	Lupin Receives Approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD lupin.com ↗
2023-06-21	Lupin Limited	Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler lupin.com ↗
2023-05-26	Lupin Limited	Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD lupin.com ↗
2022-08-26	Lupin Limited	Lupin Announces UK MHRA Approval of Lutio® (Tiotropium bromide inhalation powder) for Treatment of COPD lupin.com ↗
2021-09-03	Novartis Pharmaceuticals	Novartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions novartis.com ↗
2021-07-29	Lannett Company, Inc.	LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler® investorroom.com ↗
2021-06-15	Glenmark Pharmaceuticals Ltd. India	Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler glenmarkpharma.com ↗
2020-06-05	Novartis Pharmaceuticals	Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma novartis.com ↗
2020-02-03	Boehringer Ingelheim	New Study Further Supports the Benefits of SPIRIVA RESPIMAT in the Treatment of Asthma prnewswire.com ↗
2018-10-11	Boehringer Ingelheim	FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction prnewswire.com ↗
2018-10-11	Theravance Biopharma	Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting theravance.com ↗
2018-08-29	Glenmark Pharmaceuticals Ltd. India	Glenmark enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide dry powder inhaler in Western Europe glenmarkpharma.com ↗
2018-05-22	Niox	Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza® Phase IV and Duaklir® Phase III Studies niox.com ↗
2018-03-29	Boehringer Ingelheim	New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva® Respimat® prnewswire.com ↗
2017-11-01	GlaxoSmithKline	GSK study demonstrates superiority of Anoro Ellipta to Stiolto Respimat in improving lung function in chronic obstructive pulmonary disease gsk.com ↗
2017-09-07	AstraZeneca	Duaklir significantly improves lung function in COPD patients astrazeneca.com ↗
2017-09-07	Niox	Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease niox.com ↗
2017-05-23	Boehringer Ingelheim	New Analyses Show SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Improves Breathing for People with Asthma Regardless of BMI or Allergic Status prnewswire.com ↗
2017-02-16	Boehringer Ingelheim	FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children prnewswire.com ↗
2016-10-17	Boehringer Ingelheim	New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk prnewswire.com ↗
2016-10-12	Boehringer Ingelheim	New Support Program Provides Free Medicine and Resources for People Living with COPD Prescribed STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray prnewswire.com ↗
2016-09-06	Boehringer Ingelheim	Tiotropium RESPIMAT® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma prnewswire.com ↗
2016-09-05	Boehringer Ingelheim	Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment prnewswire.com ↗
2016-09-05	Boehringer Ingelheim	New Data: STIOLTO® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD prnewswire.com ↗
2016-08-30	AstraZeneca	AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016 astrazeneca.com ↗
2016-05-18	GlaxoSmithKline	GSK presents efficacy data for Anoro® Ellipta® in COPD patients who remained symptomatic on tiotropium gsk.com ↗
2016-04-08	Boehringer Ingelheim	Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy prnewswire.com ↗
2016-03-07	Boehringer Ingelheim	New Analyses: Adding SPIRIVA® RESPIMAT® Effective for Uncontrolled Asthma - Regardless of Allergy Subtype prnewswire.com ↗
2016-02-09	Boehringer Ingelheim	Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures prnewswire.com ↗
2016-02-03	Boehringer Ingelheim	SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents prnewswire.com ↗
2015-10-27	Boehringer Ingelheim	New Sub-Analyses Presented for STIOLTO RESPIMAT Across a Range of COPD Patient-Reported Outcomes Measures prnewswire.com ↗
2015-10-20	GlaxoSmithKline	GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD gsk.com ↗
2015-09-28	Boehringer Ingelheim	New Head-to-Head STIOLTO RESPIMAT Data Presented at ERS Annual Congress prnewswire.com ↗
2015-09-27	GlaxoSmithKline	GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint gsk.com ↗
2015-08-17	Boehringer Ingelheim	New Published Data Show STIOLTO™ RESPIMAT® Provides Clinically Meaningful Improvements in COPD Health-Related Quality of Life Measure prnewswire.com ↗
2015-05-26	Boehringer Ingelheim	FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD prnewswire.com ↗
2015-05-20	Boehringer Ingelheim	New Data Analyses on Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared to Tiotropium and Olodaterol Alone prnewswire.com ↗
2015-02-21	Boehringer Ingelheim	New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status prnewswire.com ↗
2015-01-21	Boehringer Ingelheim	SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States prnewswire.com ↗
2014-11-03	Boehringer Ingelheim	Boehringer Ingelheim Announces U.S. Filing Acceptance of New Drug Application for Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Treatment of Asthma prnewswire.com ↗
2014-10-27	Boehringer Ingelheim	Boehringer Ingelheim Presents Data for the Co-Administration of Two Approved Products for COPD Patients prnewswire.com ↗
2014-10-17	GlaxoSmithKline	Data published on Anoro® Ellipta® demonstrate improved lung function compared to tiotropium gsk.com ↗
2014-09-25	Boehringer Ingelheim	Boehringer Ingelheim Announces FDA Approval of Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Maintenance Treatment of COPD prnewswire.com ↗
2014-09-08	Boehringer Ingelheim	New Phase III Study Shows Investigational Tiotropium Improves Lung Function in Adolescent Patients with Symptomatic Asthma prnewswire.com ↗
2014-09-08	Boehringer Ingelheim	Boehringer Ingelheim Presents Pivotal Phase III Data for the Investigational Fixed-Dose Combination of Tiotropium + Olodaterol in COPD prnewswire.com ↗
2014-08-19	Boehringer Ingelheim	Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD prnewswire.com ↗
2014-08-14	Boehringer Ingelheim	FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD prnewswire.com ↗
2014-05-21	Boehringer Ingelheim	Boehringer Ingelheim Presents First Phase 3 Data on Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD prnewswire.com ↗
2014-03-01	Boehringer Ingelheim	Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma Severities prnewswire.com ↗
2013-10-28	Boehringer Ingelheim	New Data Provides Further Evidence of Lung Function Improvements in Severe Asthma with Tiotropium Delivered via the Respimat® Inhaler prnewswire.com ↗
2013-09-10	Boehringer Ingelheim	Data for Investigational Tiotropium Show Improved Lung Function and Sustained Bronchodilation in Patients with Moderate Asthma Severity prnewswire.com ↗
2013-09-08	Boehringer Ingelheim	Landmark TIOSPIR™ trial demonstrates comparable long-term safety of tiotropium delivered via Respimat® and HandiHaler® in COPD patients prnewswire.com ↗
2013-05-21	Boehringer Ingelheim	Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a Range of Symptomatic Asthma Patients at ATS 2013 prnewswire.com ↗
2013-02-23	Boehringer Ingelheim	Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status prnewswire.com ↗
2012-09-03	Boehringer Ingelheim	First Phase III Data for Tiotropium in Symptomatic Asthma Patients Treated with ICS/LABA Published in the New England Journal of Medicine prnewswire.com ↗
2012-09-03	Boehringer Ingelheim	Boehringer Ingelheim Presents First Results of Phase II Study of Investigational COPD Combination prnewswire.com ↗
2012-09-03	Almirall, S.A.	Eklira® Genuair® provides meaningful and sustained bronchodilation from the first dose. Patients prefer the Genuair® inhaler over HandiHaler® almirall.com ↗
2012-08-28	Nxera Pharma UK Limited	QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients and filings in EU and Japan by end of year nxera.life ↗
2012-05-22	Boehringer Ingelheim	Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma prnewswire.com ↗
2012-05-17	Nxera Pharma UK Limited	NVA237 Phase III GLOW2 data at American Thoracic Society (ATS) International Conference and Phase II clinical trial update nxera.life ↗
2011-06-30	Nxera Pharma UK Limited	Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD nxera.life ↗

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 340 sources stand behind the page.

Field	Value	Cited text
Known as	Tiotropium	“This pilot study was designed to evaluate the pharmacokinetic characteristics of fluticasone, salmeterol, and tiotropium after co-administration of HCP 0910 (Seretide 250...” NCT02441114 ↗ 279 “The investigators will compare the reduction in Borg dyspnea score during the 3-min constant rate shuttle walking test after 3 weeks of indacaterol 110 µg/Glycopyrronium 50 µg...” NCT02567214 ↗ “The primary objective of this study is to evaluate the efficacy and safety of orally inhaled tiotropium and olodaterol as both a fixed dose combination and a free combination...” NCT02030535 ↗ “Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive...” NCT03265145 ↗ “Tiotropium, a once-daily long-acting anticholinergic agent, has been shown to be an efficacious and safe add-on treatment for adults with symptomatic asthma, despite treatment...” PMID 25081651 ↗ Jul 2014 “patients were randomized to receive either tiotropium 5 μg or a fixed-dose combination of tiotropium 5 μg with olodaterol 2 μg, 5 μg, or 10 μg, delivered once daily via the...” PMID 30843141 ↗ Mar 2019 “Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent...” NCT02799784 ↗ “Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics:...” NCT02165826 ↗ “An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of...” NCT03097380 ↗ “Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.” NCT03169504 ↗ “Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device” NCT05927155 ↗ Show 269 more sources
Known as	Ba 79 BR	“The objective of this study is to investigate the long-term safety of Ba 79 BR (tiotropium) powder inhalation” NCT02172430 ↗
Known as	Ba679BR	“A Multiple Dose Comparison of 18 µg, 36 µg of Ba679BR (Tiotropium) Inhalation Capsules and Oxitropium Metered Dose Inhaler (2 Puffs of 100µg) in a 4-week, Double-Blind,...” NCT02172807 ↗ 3 “Tiotropium (Ba679 BR)” NCT02172287 ↗ NCT00292448 ↗ NCT02172352 ↗
Known as	Bromuro de Tiotropio	“The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of...” NCT00144326 ↗ 2 “daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.” NCT00144339 ↗ “tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio)” NCT00157235 ↗
Known as	GSP304	“GSP304 (tiotropium bromide) Inhalation Solution” NCT03118765 ↗
Known as	Neng Beile	“Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）” NCT05295355 ↗
Known as	Si Lihua	“Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）” NCT05295355 ↗
Known as	Spiriva	“The purpose of the study is to determine the efficacy and safety of the combination of ADVAIR DISKUS® 250/50mcg (FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT) plus...” NCT00784550 ↗ 42 “The investigators will compare the reduction in Borg dyspnea score during the 3-min constant rate shuttle walking test after 3 weeks of indacaterol 110 µg/Glycopyrronium 50 µg...” NCT02567214 ↗ “The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of...” NCT00144326 ↗ “The purpose of this study is to investigate the effect of a 9-month treatment of tiotropium (SPIRIVA®) 18 mcg once daily on Health Related Quality of Life and lung function in...” NCT00274053 ↗ “To evaluate acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of...” NCT00274066 ↗ “Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule,...” NCT03745261 ↗ “daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.” NCT00144339 ↗ “tiotropium 18 μg, formulated as inhalation powder in the hard gelatine capsule and delivered via the HandiHaler® (Spiriva®) following single dose inhalation” NCT02242266 ↗ “Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®)” NCT02467452 ↗ “Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD” NCT00239447 ↗ “a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®]” NCT02254174 ↗ Show 32 more sources
Known as	Spiriva HandiHaler	“a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®]” NCT02254174 ↗ 7 “Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days” NCT01085045 ↗ “open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)” NCT01854645 ↗ “Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)” NCT01970878 ↗ “tiotropium (delivered by the Handihaler® as Spiriva Handihaler®)” NCT01696058 ↗ “Tiotropium (Spiriva® HandiHaler®, 18 µg Once Daily)” NCT01072396 ↗ “Open-label drug also known as Spiriva HandiHaler” NCT01124422 ↗ “18 mcg tiotropium (Spiriva HandiHaler) daily” NCT00525512 ↗
Known as	Spiriva Respimat	“The purpose of this clinical trial is to evaluate the efficacy and safety of inhaled tiotropium bromide (Spiriva Respimat) in preterm-born children and adolescents suffering...” NCT07827859 ↗ 5 “Tiotropium (Spiriva® Respimat®, Boehringer Ingelheim International) is approved as a once-daily maintenance treatment of asthma” NCT04990167 ↗ “tiotropium Respimat® (Spiriva® Respimat®) 5 microgram (μg) once daily for a duration of 4 weeks” NCT03964207 ↗ “Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)” NCT02347072 ↗ “tiotropium bromide monohydrate (Spiriva Respimat)” NCT04648813 ↗ NCT03358147 ↗
Known as	SpirivaTM	“Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily” NCT01397890 ↗
Known as	T18GEL	“18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S\_DPI) twice daily (BID)” NCT00662792 ↗
Known as	TIO	“The long-acting muscarinic antagonists umeclidinium (UMEC) and tiotropium (TIO) are approved once-daily maintenance therapies for COPD.” PMID 27103795 ↗ Apr 2016 5 “with tiotropium bromide (TIO), 18 μg, on aPWV.” PMID 25058845 ↗ Dec 2014 “compared with tiotropium (TIO) 18 mcg/day” PMID 27796912 ↗ Oct 2016 “antimuscarinic tiotropium bromide (TIO)” PMID 20580216 ↗ Jun 2010 “once-daily tiotropium (TIO) 18 µg” PMID 25841237 ↗ Apr 2015 “Tiotropium 18 μg (TIO 18 μg)” NCT02796677 ↗
Known as	Tio18GEL	“18 µg Tiotropium (Tio18GEL) inhalation powder” NCT00662792 ↗ 1 “tiotropium (Tio18GEL)” NCT00668772 ↗
Known as	tiotropium bromide	“A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the...” NCT01483625 ↗ 73 “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “The objective of this trial is to evaluate whether the effect of one year (48 weeks) treatment with inhaled tiotropium bromide (Spiriva® - 18 µg once daily) on the change in...” NCT00277264 ↗ “The objectives of this study were to evaluate the effect of a one-year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function, incidence and severity of...” NCT00274014 ↗ “A total of 839 patients with COPD who satisfied the eligibility criteria were randomly assigned (1:1) to receive a once daily inhaled capsule of either tiotropium bromide (18...” PMID 24549160 ↗ Feb 2014 “The purpose of this clinical trial is to evaluate the efficacy and safety of inhaled tiotropium bromide (Spiriva Respimat) in preterm-born children and adolescents suffering...” NCT07827859 ↗ “Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration...” NCT01120691 ↗ “Proof of Concept Evaluation of Drug-Device Interaction With Aclidinium Bromide Via Genuair® and Tiotropium Bromide Via HandiHaler® in COPD Using Impulse Oscillometry” NCT02039050 ↗ “Tiotropium bromide, long-acting muscarinic antagonist (LAMA). Administered as 2.5 μg per actuation, 2 inhalations once daily via Respimat inhaler for 28 days.” NCT07541378 ↗ “Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®)” NCT02467452 ↗ “single inhaled doses of GSK573719 (250, 500 and 1000 μg) and Tiotropium Bromide (18 μg) Via DPI in COPD Patients.” NCT00515502 ↗ Show 63 more sources
Known as	Tiotropium Bromide Monohydrate	“Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent...” NCT02799784 ↗ 4 “Micronized Tiotropium Bromide Monohydrate 22.5 mcg” NCT02441114 ↗ “tiotropium bromide monohydrate (Spiriva Respimat)” NCT04648813 ↗ NCT03400241 ↗ NCT05246046 ↗
Known as	Tiotropium Bromide Powder for Inhalation (Spiriva)	“Tiotropium Bromide Powder for Inhalation (Spiriva®)” NCT03169504 ↗
Known as	Tiotropium BromideInhalation Aerosol Suspension	“Tiotropium BromideInhalation Aerosol Suspension” NCT05295355 ↗
Known as	Tiotropium Respimat	“Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study” PMID 24890738 ↗ Jun 2014
Known as	tiotropium: Spiriva	“tiotropium: Spiriva” NCT00864812 ↗
Action	Inhibit	“the long-acting anticholinergic tiotropium” PMID 21807250 ↗ Aug 2011
Modality	Other / unclassified	“once-daily long-acting anticholinergic” PMID 27812637 ↗ Sep 2016
Route	Inhaled	“Tiotropium Bromide Inhalation Powder” NCT00106821 ↗